Listing 1 - 7 of 7 |
Sort by
|
Choose an application
Choose an application
Choose an application
Pharmacotherapy. --- Rifampin. --- Rifamycin, Congresses. --- Tuberculosis, Chemotherapy, Congresses. --- Tuberculosis.
Choose an application
The Special Issue of the journal Diagnostics entitled “Challenges and Advances in Tuberculosis and Mycobacterial Lung Diseases” encompasses research articles, case presentations, and literature reviews concerning the epidemiology, medical surveillance, as well as diagnostic and therapeutic challenges in tuberculosis (TB) and in the infections caused by non-tuberculous mycobacteria (NTM ). The articles present the current status of knowledge concerning the use of molecular tests and genotyping of M. tuberculosis for the rapid identification of MDR and XDR clones, the advances in the identification of NTM and their differentiation to the species level, as well as clinical studies performed in TB and NTM risk groups. In addition, a summary of current recommendations concerning diagnosis and treatment of tuberculous pericarditis is presented.
Public health & preventive medicine --- Gordonia bronchialis --- microbiological diagnostics --- respiratory infection --- Mycobacterium tuberculosis --- drug resistance --- XDR-tuberculosis --- household TB transmission --- tuberculous pericarditis --- extrapulmonary tuberculosis --- pericarditis --- constrictive pericarditis --- tuberculosis --- abscess --- scrofula --- head and neck --- epiglottis --- larynx --- airway --- mycobacteria --- surgical drainage --- FluoroType MTBDR --- molecular --- isoniazid --- rifampin --- bacillus Calmette-Guerin --- bladder cancer immunotherapy --- BCGosis --- BCG pulmonary infection --- severe respiratory insufficiency --- nontuberculous mycobacterium --- lung cancer --- surgery --- nontuberculous mycobacteria --- cystic fibrosis --- chest computed tomography --- Beijing-TB --- Beijing-like genotype --- Mycobacterium chimaera --- nontuberculous mycobacterial disease --- silicosis --- extracorporeal membrane oxygenation --- COVID-19 pandemic --- spoligotyping --- Poland --- human immunodeficiency virus --- acquired immunodeficiency syndrome --- chest imaging --- rapidly growing mycobacteria --- antimicrobial resistance --- broth microdilution --- minimal inhibitory concentration (MIC)
Choose an application
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.
Research & information: general --- Biology, life sciences --- mycobacteria --- tuberculosis --- multi-drug resistance --- drug discovery --- promiscuous targets --- Mycobacterium tuberculosis --- rifampin --- isoniazid --- mechanisms of resistance --- mutations --- granulomas --- caseum --- cell envelope --- dormancy --- delpazolid --- macozinone --- DprE1 inhibitor --- clinical studies --- discovery --- mode of action --- drug resistance --- toxicity --- target --- energy metabolism --- electron transport chain --- oxidative phosphorylation --- bedaquiline --- Q203 --- MID3 --- pharmacokinetics --- pharmacodynamics --- drug-drug interactions --- in vitro --- in vivo --- drug development --- tuberculosis treatment --- biomarkers --- drug combination --- clinical trial --- BCG --- tuberculosis vaccines --- TBVI --- EDCTP --- IAVI --- CTVD --- host-directed therapy --- anti-virulence compounds --- TB --- post-treatment sequelae --- surgery --- pulmonary rehabilitation --- Carlo Forlanini --- artificial pneumothorax --- n/a --- structure-based drug design --- target-based drug design --- PknB --- PknG --- DNA gyrase --- antibiotic --- mycobacterium --- genomics --- transcriptomics --- proteomics --- metabolomics --- lipidomics --- target identification --- mechanism of action --- antimicrobial drug resistance (AMR) --- target-based screening --- phenotypic screening --- antituberculosis agents --- antimycobacterial --- anti-TB drug pipeline --- privileged targets --- lead generation
Choose an application
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.
mycobacteria --- tuberculosis --- multi-drug resistance --- drug discovery --- promiscuous targets --- Mycobacterium tuberculosis --- rifampin --- isoniazid --- mechanisms of resistance --- mutations --- granulomas --- caseum --- cell envelope --- dormancy --- delpazolid --- macozinone --- DprE1 inhibitor --- clinical studies --- discovery --- mode of action --- drug resistance --- toxicity --- target --- energy metabolism --- electron transport chain --- oxidative phosphorylation --- bedaquiline --- Q203 --- MID3 --- pharmacokinetics --- pharmacodynamics --- drug-drug interactions --- in vitro --- in vivo --- drug development --- tuberculosis treatment --- biomarkers --- drug combination --- clinical trial --- BCG --- tuberculosis vaccines --- TBVI --- EDCTP --- IAVI --- CTVD --- host-directed therapy --- anti-virulence compounds --- TB --- post-treatment sequelae --- surgery --- pulmonary rehabilitation --- Carlo Forlanini --- artificial pneumothorax --- n/a --- structure-based drug design --- target-based drug design --- PknB --- PknG --- DNA gyrase --- antibiotic --- mycobacterium --- genomics --- transcriptomics --- proteomics --- metabolomics --- lipidomics --- target identification --- mechanism of action --- antimicrobial drug resistance (AMR) --- target-based screening --- phenotypic screening --- antituberculosis agents --- antimycobacterial --- anti-TB drug pipeline --- privileged targets --- lead generation
Choose an application
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.
Research & information: general --- Biology, life sciences --- mycobacteria --- tuberculosis --- multi-drug resistance --- drug discovery --- promiscuous targets --- Mycobacterium tuberculosis --- rifampin --- isoniazid --- mechanisms of resistance --- mutations --- granulomas --- caseum --- cell envelope --- dormancy --- delpazolid --- macozinone --- DprE1 inhibitor --- clinical studies --- discovery --- mode of action --- drug resistance --- toxicity --- target --- energy metabolism --- electron transport chain --- oxidative phosphorylation --- bedaquiline --- Q203 --- MID3 --- pharmacokinetics --- pharmacodynamics --- drug-drug interactions --- in vitro --- in vivo --- drug development --- tuberculosis treatment --- biomarkers --- drug combination --- clinical trial --- BCG --- tuberculosis vaccines --- TBVI --- EDCTP --- IAVI --- CTVD --- host-directed therapy --- anti-virulence compounds --- TB --- post-treatment sequelae --- surgery --- pulmonary rehabilitation --- Carlo Forlanini --- artificial pneumothorax --- structure-based drug design --- target-based drug design --- PknB --- PknG --- DNA gyrase --- antibiotic --- mycobacterium --- genomics --- transcriptomics --- proteomics --- metabolomics --- lipidomics --- target identification --- mechanism of action --- antimicrobial drug resistance (AMR) --- target-based screening --- phenotypic screening --- antituberculosis agents --- antimycobacterial --- anti-TB drug pipeline --- privileged targets --- lead generation --- mycobacteria --- tuberculosis --- multi-drug resistance --- drug discovery --- promiscuous targets --- Mycobacterium tuberculosis --- rifampin --- isoniazid --- mechanisms of resistance --- mutations --- granulomas --- caseum --- cell envelope --- dormancy --- delpazolid --- macozinone --- DprE1 inhibitor --- clinical studies --- discovery --- mode of action --- drug resistance --- toxicity --- target --- energy metabolism --- electron transport chain --- oxidative phosphorylation --- bedaquiline --- Q203 --- MID3 --- pharmacokinetics --- pharmacodynamics --- drug-drug interactions --- in vitro --- in vivo --- drug development --- tuberculosis treatment --- biomarkers --- drug combination --- clinical trial --- BCG --- tuberculosis vaccines --- TBVI --- EDCTP --- IAVI --- CTVD --- host-directed therapy --- anti-virulence compounds --- TB --- post-treatment sequelae --- surgery --- pulmonary rehabilitation --- Carlo Forlanini --- artificial pneumothorax --- structure-based drug design --- target-based drug design --- PknB --- PknG --- DNA gyrase --- antibiotic --- mycobacterium --- genomics --- transcriptomics --- proteomics --- metabolomics --- lipidomics --- target identification --- mechanism of action --- antimicrobial drug resistance (AMR) --- target-based screening --- phenotypic screening --- antituberculosis agents --- antimycobacterial --- anti-TB drug pipeline --- privileged targets --- lead generation
Listing 1 - 7 of 7 |
Sort by
|